中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2014年
9期
641-645
,共5页
角膜疾病%述评
角膜疾病%述評
각막질병%술평
Corneal diseases%Editorial
角膜病是我国的第二大致盲眼病,目前角膜盲最难解决的瓶颈问题是角膜供体严重不足并缺乏技术推广和培训平台和体系,从事角膜病的专业人才短缺.近5年,我国在角膜病的基础和临床方面的研究已取得较大成绩,尤其在感染性角膜病方面对真菌性角膜炎发病机制和临床治疗研究,已在国际上占有一席之地.此外,在组织工程角膜和脱细胞基质角膜的研究方面,临床研究已取得了较好的初步效果.角膜屈光手术的临床研究几乎和国际先进水平同步,而角膜内皮移植技术在我国还未真正得到普及.人工角膜的临床应用及研制相对落后,仅在极少数单位有限开展;角膜胶原交联术可减缓早期圆锥角膜的发展,在欧洲已被广泛应用于临床,但后两者在我国仍未得到国家管理部门的批准.
角膜病是我國的第二大緻盲眼病,目前角膜盲最難解決的瓶頸問題是角膜供體嚴重不足併缺乏技術推廣和培訓平檯和體繫,從事角膜病的專業人纔短缺.近5年,我國在角膜病的基礎和臨床方麵的研究已取得較大成績,尤其在感染性角膜病方麵對真菌性角膜炎髮病機製和臨床治療研究,已在國際上佔有一席之地.此外,在組織工程角膜和脫細胞基質角膜的研究方麵,臨床研究已取得瞭較好的初步效果.角膜屈光手術的臨床研究幾乎和國際先進水平同步,而角膜內皮移植技術在我國還未真正得到普及.人工角膜的臨床應用及研製相對落後,僅在極少數單位有限開展;角膜膠原交聯術可減緩早期圓錐角膜的髮展,在歐洲已被廣汎應用于臨床,但後兩者在我國仍未得到國傢管理部門的批準.
각막병시아국적제이대치맹안병,목전각막맹최난해결적병경문제시각막공체엄중불족병결핍기술추엄화배훈평태화체계,종사각막병적전업인재단결.근5년,아국재각막병적기출화림상방면적연구이취득교대성적,우기재감염성각막병방면대진균성각막염발병궤제화림상치료연구,이재국제상점유일석지지.차외,재조직공정각막화탈세포기질각막적연구방면,림상연구이취득료교호적초보효과.각막굴광수술적림상연구궤호화국제선진수평동보,이각막내피이식기술재아국환미진정득도보급.인공각막적림상응용급연제상대락후,부재겁소수단위유한개전;각막효원교련술가감완조기원추각막적발전,재구주이피엄범응용우림상,단후량자재아국잉미득도국가관리부문적비준.
In China,corneal disease is currently the second leading cause of blindness.Severe donor shortage,insufficient technique supports and promotion,and the lack of corneal disease specialists due to poor systematic training are all urgent problems to be resolved.The last 5 years have witnessed a considerable progress in basic and clinical researches of corneal disease.Investigations on the pathogenesis and treatment of fungal keratitis have won an international reputation.Results from the study of corneal reconstruction with tissue-engineered and acellular matrix corneas have been tested in clinical trials with good preliminary performance.Moreover,the clinical researches of corneal refractive surgery have kept pace with the latest international progresses.However,Descemet's membrane endothelial keratoplasty needs further promotion,and the development and application of keratoprosthesis remains a blank.Although keratoprosthesis and corneal collagen cross-linking have been widely applied in Europe with satisfactory clinical efficacy,they are still under assessment by China Food and Drug Administration for approval of use.